eCommons@AKU
Department of Obstetrics & Gynaecology

Division of Woman and Child Health

March 2010

Pregnancy outcome in women with
antiphospholipid syndrome on low-dose aspirin
and heparin: a retrospective study.
T. Naru
Aga Khan University

Rozilla Sadia Khan
Aga Khan University

R. Ali
Aga Khan University

Follow this and additional works at: https://ecommons.aku.edu/
pakistan_fhs_mc_women_childhealth_obstet_gynaecol
Part of the Maternal and Child Health Commons
Recommended Citation
Naru, T., Khan, R., Ali, R. (2010). Pregnancy outcome in women with antiphospholipid syndrome on low-dose aspirin and heparin: a
retrospective study.. Eastern Mediterranean Health Journal = La Revue De Sante De La Mediterranee Orientale = Al-Majallah Al-ṣiḥḥiyah
Li-Sharq Al-Mutawassiṭ, 16(3), 308-312.
Available at: https://ecommons.aku.edu/pakistan_fhs_mc_women_childhealth_obstet_gynaecol/36

EMHJ • Vol. 16

No. 3 • 2010

Eastern Mediterranean Health Journal
La Revue de Santé de la Méditerranée orientale

Pregnancy outcome in women with antiphospholipid
syndrome on low-dose aspirin and heparin: a
retrospective study
T. Naru,1 R.S. Khan 1 and R. Ali 1

 دراسة:نتائج احلمل لدى املصابات بمتالزمة مضادات الفوسفولبيد الاليت يعاجلن بجرعة منخفضة من األسربين واهليبارين
استعادية
 رمحت عيل، روزيال صديقة خان،طاهرة ناور

 هذه دراسة استعادية لسجالت املستشفى لتحليل نتائج احلمل بعد معاجلتني خمتلفتني للحوامل املصابات بإسقاط حديث التشخيص مع:اخلالصـة
 وقد اعترب من املضاعفات التي. منهن األسربين واهليبارين35  تلقت، امرأة64  وقد شملت الدراسة.متالزمة مضادات الفوسفولبيد يف احلمل املشار إليه
 ومل يكن هناك اختالفات. وموت الوليد، ونقص النمو داخل الرحم، واخلداج،تصيب األمهات واألجنّة كل من ارتفاع ضغط الدم املحرض باحلمل
 وباملقابل هناك اختالفات يُعْ تَدُّ هبا إحصائي ًا يف املستويات الوسطية.يُعْ تَدُّ هبا إحصائي ًا يف املضاعفات عند األمهات أو أثناء احلمل لدى املجموعات
 وقد كان إعطاء األسربين لوحده أو بالتشارك مع اهليبارين ذي نجاعة (كفاءة) متساوية لدى.للمضادات من الربوتينات املناعية جي للكارديوليبني
.املصابات بمتالزمة مضادات الفسفولبيد وإسقاطات متكررة

ABSTRACT This retrospective review of hospital records analysed pregnancy outcome with 2 different treatments
for women with recurrent miscarriage diagnosed with antiphospholipid syndrome in the index pregnancy. Of
64 women, 29 had received aspirin and 35 aspirin plus heparin. Pregnancy-induced hypertension, prematurity,
intrauterine growth restriction and neonatal death were considered as maternal and fetal complications. There
were no significant differences in antenatal and maternal complications between the groups. However, there
were significant differences in mean anticardiolipin IgG antibody levels. Aspirin alone or in combination with
heparin was equally efficacious in women with antiphospholipid syndrome and recurrent miscarriage.

Issue de la grossesse de femmes présentant un syndrome des anticorps antiphospholipides traité par
l’aspirine à faible dose et par l’héparine : une étude rétrospective
RÉSUMÉ Cette étude rétrospective des dossiers hospitaliers a analysé l’issue de la grossesse chez des femmes
ayant fait des fausses couches à répétition, chez lesquelles un syndrome des anticorps antiphospholipides a
été diagnostiqué et qui ont reçu deux traitements différents. Sur 64 femmes, 29 d’entre elles avaient reçu de
l’aspirine, tandis que 35 étaient traitées avec de l’aspirine et de l’héparine. L’hypertension induite par la grossesse,
la prématurité, les retards de croissance intra-utérine et les décès néonatals ont été considérés comme des
complications maternelles et fœtales. Aucune différence significative en termes de complications prénatales et
maternelles n’a été constatée entre les deux groupes. Cependant, des différences importantes ont été observées
dans les taux moyens d’anticorps anticardiolipine IgG. L’aspirine seule possède la même efficacité que l’aspirine
associée à l’héparine chez les femmes présentant un syndrome des anticorps antiphospholipides et ayant fait des
fausses couches à répétition.
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Introduction
Antiphospholipid antibody syndrome
(APS) is a disorder characterized by
the presence of medium to high levels of lupus anticoagulant antibodies
(LAC) and anticardiolipin antibodies
(aCL)—the so-called antiphospholipid antibodies (aPL). APS was first
described in the early 1980s in patients
with systemic lupus erythematosus
[1,2] and is termed primary APS when
it occurs in otherwise healthy people
[3]. APS is associated with arterial and
venous thrombosis and both early pregnancy loss and fetal death in advanced
pregnancy [1–4]. While placental
thrombosis and infarction are common
findings in aPL-related intrauterine fetal
deaths [4], thrombosis is not a universal
finding and alternative mechanisms of
pregnancy loss have been sought [5,6].
Prospective clinical studies have
confirmed that aPL are risk factors for
pregnancy loss, both in patients with
systemic lupus erythematosus [5] and
in healthy nulliparous women [7]. In
women with a history of 3 or more consecutive pregnancy losses persistently
positive tests for aPL were found in up to
15%, and in these cases, subsequent fetal
loss rates of up to 60%–90% were noted
without specific treatment [8,9]. aPL
are also associated with a high incidence
of pre-eclampsia, intrauterine growth
restriction (IUGR), fetal distress and
premature delivery [10,11].
A number of studies have evaluated
the efficacy of treatment with low-dose
aspirin, prednisolone, unfractionated
low-molecular weight heparin and most
recently intravenous gammaglobulin,
either alone or in various combinations.
However, the findings have not been
consistent [12,13]. Low-dose aspirin in
combination with heparin was demonstrated in 2 randomized controlled trials
to lead to a significant improvement in
the live birth rate [14,15].
This study aimed to determine the
pregnancy outcome in women with
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APS and recurrent pregnancy loss who
were treated with aspirin alone or aspirin in combination with heparin during
the index pregnancy.

Methods
Sample and setting

This study was conducted at the Aga
Khan University Hospital in Karachi,
Pakistan, a tertiary care unit with an
average of 3500 deliveries per year. A
dedicated outpatient service caters to
high-risk obstetric care, early pregnancy
complications and investigations including Doppler ultrasound facilities in
the fetomaternal unit. The nursing staff
provides regular antenatal sessions as
well as patient education and training
for self-administered injections.
The criteria for entry to the study
were women who suffered 2 or more
1st or 2nd trimester fetal deaths or at
least 1 intrauterine death or neonatal
death and 1 of the following laboratory
findings before or during the index pregnancy: aCL > 5 GPL [IgG phospholipid
units] or > 5 MPL [IgM phospholipid
units].
Data collection

The study was a retrospective analysis
of women who voluntarily chose different treatments. From January 1994 to
December 2003 the data were retrieved
from a data indexing and coding system
based on the International classification
of diseases, 9th edition. Of 84 women
identified, 20 were excluded due to
incomplete documentation and the
remaining 64 women were divided into
2 groups: group A (n = 29) had received
low-dose aspirin (75 mg once daily
orally) while group B (n = 35) had received aspirin (75 mg once daily orally)
plus heparin (5000 IU subcutaneously
twice daily) (group B) during the index pregnancy. The group of patient
on aspirin treatment alone were those
who had refused heparin, as injections
were not acceptable to them. Aspirin

had been commenced from the start
of the pregnancy either after a positive
pregnancy test or presence of cardiac
activity on ultrasound scan until the
34th week of gestation, while in group
B heparin had been started in the 2nd
trimester and continued until the 36th
week of gestation.
Most of the women were assessed
before pregnancy when they came to
the clinic for counselling regarding more
than 2 pregnancy losses (intrauterine
and/or neonatal deaths). Women were
monitored fortnightly during the 1st trimester for hypertension and thrombocytopenia. Fetal monitoring was started
from 24–26 weeks with monthly growth
scans until delivery. Two-weekly scans
were performed if severe early onset of
IUGR was suspected along with umbilical artery Doppler studies. The timing
of delivery was assessed individually on
the basis of current and past obstetric
history and the onset of complications,
e.g. pre-eclampsia, IUGR or abnormal
Doppler results. Women whose pregnancy reached 37 completed weeks
gestation were either induced or delivered by elective caesarean section. In
women who received heparin during
pregnancy, the treatment was used until
the end of the hospital stay and lowdose aspirin was continued until 6–8
weeks postpartum.
Analysis

The data were analysed using SPSS,
version 10. Independent sample t-tests
were used to compare 1st, 2nd and 3rd
trimester pregnancy losses, neonatal
deaths and status of aPL. Chi-squared
and Fisher exact tests were used for
the association between maternal age,
gestational age, birth weight, status of
aPL and pregnancy outcome. A P-value
< 0.05 was considered significant.

Results
A total of 64 women with APS and
recurrent miscarriage were included in
309
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Table 1 Age and pregnanacy characteristics of women treated with aspirin or aspirin plus heparin (n = 64)
Characteristic

Group A

Group B

Aspirin (n = 29)

Aspirin + heparin (n = 35)

Mean (SD)

Mean (SD)

P-value

Maternal age (years)

28.8 (5.3)

29.6 (5.2)

0.575

1st and 2nd trimester pregnancy loss (No.)

2.28 (1.13)

2.43 (2.10)

0.726

3rd trimester pregnancy loss (No.)

0.21 (0.41)

0.34 (0.39)

0.300

Neonatal death (No.)

0.28 (0.53)

0.20 (0.47)

0.547

SD = standard deviation.

the study: 29 women in group A used
only low-dose aspirin and 35 women in
group B received low-dose aspirin plus
heparin. Tables 1 and 2 show the demographic details and antiphospholipid
antibody status of the women. There
were no significant differences between
the groups with respect to maternal age,
number of previous 1st, 2nd and 3rd
trimester pregnancy losses and neonatal
deaths.
There was a significant difference in
the mean concentrations of aCL IgG
titres between group A and group B
[8.88 (SD 7.17) GPL versus 15.88 (SD
13.77) GPL] (P = 0.016) (Table 2).
The mean concentrations of aCL IgM
titres were not significantly different
between the groups [10.73 (SD 7.19)
MPL versus 12.30 (SD 7.61) MPL] (P
= 0.403).
There were no significant differences between groups A and B in the
rates of pre-eclampsia [6/29 (20.7%)
versus 10/35 (28.6%)], preterm births
[9/29 (31.0%) versus 12/35 (34.3%)]
and IUGR [5/29 (17.2%) versus 8/35
(22.9%)] (Table 3).
The mean gestational age and the
neonatal birth weight were not significantly different between the groups;

the mean gestational ages at delivery
in groups A and B were 35.9 (SD 4.1)
months and 35.6 (SD 3.6) months respectively. The mean birth weights in
groups A and B were 2.47 (SD 0.85)
kg and 2.36 (SD 0.77) kg respectively.
There were 6 neonatal deaths (20.7%)
in group A and 3 (8.3%) in group B. One
baby in group A died due to congenital
heart disease (Table 3). None of the
women developed a thromboembolic
or cerebrovascular event.

Discussion
APS is widely recognized as a risk factor
for numerous obstetric complications,
including recurrent miscarriage, IUGR,
pre-eclampsia, fetal death and preterm
labour. Since its original description,
APS has emerged as the most important treatable cause of recurrent miscarriage [2]. The prevalence of aPL in
recurrent miscarriage is approximately
15.5% [9,16]. The risk of subsequent
pregnancy loss in women with aPL and
previous pregnancy loss is unknown but
probably exceeds 60% [10].
A variety of treatment regimens
have been used, both single agents and

combinations, to improve the poor live
birth rates among these women, with
live births reported from 30% to 100%
of pregnancies [1]. However, treatment
of pregnant aPL-positive women to
improve pregnancy outcome remains
completely empirical. The paucity of
data from large well-designed trials of
different management options in comparable groups of pregnant women with
this complex disease contributes to the
difficulty in formulating recommendations for managing these pregnancies.
The approach is guided by observational studies, personal knowledge and
the opinions of others experienced in
the management of such women.
Our study investigated women with
APS in the index pregnancy treated
with either aspirin alone or aspirin and
heparin together. Analysis of the data
did not reveal any statistically significant
difference between the treatment groups
in terms of live birth rate or the antenatal
complication rates. Preterm deliveries
were experienced by 31.0% of women in
group A compared with 34.3% in group
B, while 17.2% and 22.9% of women suffered IUGR in groups A and B respectively. Similarly, severe pre-eclampsia
was observed in 20.7% and 28.6% of

Table 2 Antiphospholipid antibody levels of women treated with aspirin or aspirin plus heparin (n = 64)
Antibody levels

Group A

Group B

Aspirin (n = 29)

Aspirin + heparin (n = 35)

Anticardiolipin IgG (GPL)
Cardiolipin IgM (MPL)
SD = standard deviation; GPL = IgG phospholipid units; MPL = IgM phospholipid units.
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P-value

Mean (SD)

Mean (SD)

8.88 (7.17)

15.88 (13.77)

0.016

10.73 (7.19)

12.30 (7.61)

0.403
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Table 3 Maternal and fetal outcomes of index pregnancies of women treated with aspirin or aspirin plus heparin
Maternal and fetal outcome

Group A

Group B

P-value

Aspirin (n = 29)

Aspirin + heparin (n = 35)

Pre-eclampsia (No.)

6

10

0.568

Preterm delivery (No.)

9

12

0.498

a

Small-for-gestational age baby (No.)

5

8

0.757

Gestational age [Mean (SD) weeks]

35.9 (4.2)

35.6 (3.6)

0.720

Birth weight [Mean (SD) g]

2.5 (0.9)

2.4 (0.8)

0.581
0.152

Neonatal death (No.)
Yes

6b

3

No

23

32

At 26–37 weeks.
1 baby had congenital heart disease.
SD = standard deviation.
a

b

the women respectively. These results
are comparable to international data
[11,12,16,17].
Stone et al. analysed the outcome
of pregnancies after introduction of a
standard protocol in 33 patients with
APS and achieved a live birth rate of
91% in women with primary APS even
in those with significant past pregnancy
morbidity with or without thrombosis.
The outcome in the index pregnancy
was influenced the most by past pregnancy outcome [18]. Branch and Khamashta pointed out that treatment of
APS must be individualized and related
to previous pregnancy complications
[19].
A prospective study of aPL-positive
pregnant women with at least 3 spontaneous consecutive miscarriages recorded
44% of live births in women assigned to
low-dose aspirin alone and 80% for those
treated with aspirin plus subcutaneous
heparin twice daily [14]. A comparable
trial also found aspirin alone inferior to
aspirin plus heparin (42% versus 71% live
births) [15]. In view of the heterogeneous definition of aPL in the literature,

Kutteh excluded women with LAC [14],
whereas in the study of Rai et al., 80% of
the patients had LAC in the absence of
aCL [15]. Meanwhile, Farquharson et al.
found the birth rate to be similar in both
groups (72% with aspirin alone compared
with 78% when heparin was added to the
regimen) [20]. The uncertainty as to
whether heparin is always needed comes
from this uncontrolled prospective study
with 91% live births with low-dose aspirin
alone in aPL-positive pregnant women,
who had a minimum of 2 spontaneous
abortions and a history of only 6% live
births [18]. Differences in the inclusion
and exclusion criteria used in different
studies are a major cause of such discordant findings [21].
Our study suggests that the women
with aPL and recurrent pregnancy loss
can be treated effectively with low-dose
aspirin alone. As this study did not include untreated controls, we cannot
exclude the possibility that aspects of
obstetric care other than the treatment
per se influenced pregnancy outcome.
An important finding in this study
was the statistical significant difference

in the IgG values between the aspirin
group and the aspirin plus heparin
group (P = 0.016). The maternal and
fetal complications in the 2 groups were
similar. We cannot exclude the possibility of a better outcome in the aspirin
and heparin group due to the addition
of heparin. The persistent presence of
IgG and IgM aCL needs to be clinically monitored during pregnancy for
optimal outcome. This may have some
implications for further study and counselling of these women.
As complications still occur and
the exact pathogenetic mechanism of
these events in APS remains unclear,
further randomized trials are required
to determine the optimum regime for
the management of APS pregnancies.
Among combination therapies, aspirin
together with heparin is currently one
of the best treatments offered, with the
fewest adverse drug effects. The possibility of adverse effects with heparin
therapy for a longer duration, and the
cost implications for low resource areas
needs consideration.
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Mental health aspects of women’s reproductive health. A global review of the literature
This book has reviewed the research undertaken on a broad range of reproductive health issues and their mental health
determinants/consequences over the last 15 years from both high- and low-income countries. Evidence from peerreviewed journals has been used wherever possible but has been augmented with results of a specific survey initiated to
gather state of the art information on reproductive and mental health issues from a variety of researchers and interested
parties. Valuable data from consultant reports, national programme evaluations and postgraduate research work was also
compiled, analyzed and synthesized.
Further information about this and other WHO publications can be found at: http://www.who.int/publications/en/
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